In this application, we propose to investigate genomic heterogeneity within oral squamous cell carcinomas (OSCC) towards defining a cancer initiating cell (CIC) molecular signature that will advance our diagnostic and therapeutic armamentarium. Specifically, this work will address the NIDCR FOA on Functional Characterization of Oral Cancer Initiating Cells that emphasizes a critical need for the "elucidation of specific OSCC CIC signature". CICs are proposed to contribute to treatment resistance and metastasis but many of their features are defined by phenotypes only and a thorough molecular understanding of what drives their aggressive behavior is lacking. We developed a mouse oral cancer (MOC) cell line model that has many conserved features with human OSCC. Overlapping features included CD44 expression and increased ERK1/2 activation in aggressive lines that paralleled human CIC populations. We translated these findings into a clinical trial where patients with OSCC receive trametinib, a MEK/ERK inhibitor, with the goal of targeting CIC populations. In addition, using exome sequencing of MOC lines, we found common driver pathways described in human OSCC. Expression microarray analysis then defined a MOC molecular signature of aggressiveness and metastasis that we call the Oral Cancer Metastasis Predictor (OCMP). This OCMP stratified human OSCC patients from three independent datasets comprising 321 patients into those with good outcomes and those with poor outcomes. Finally, we generated preliminary exome data from sorted human OSCC that in part paralleled findings in MOC lines. To test the hypothesis that the OCMP is a CIC specific imprint, we propose to use RNA capture sequencing to define the genomic heterogeneity within human OSCC. This approach will be the first to sort primary human OSCC into CIC and non-CIC populations and directly interrogate them with genomic approaches. These data will help refine the OCMP and likely identify other vulnerabilities within CIC populations. Similarly, we will interrogate patient samples from the trametinib clinical trial, to assess whether MEK inhibition has an impact on the CIC signature within tumors. Finally, we will examine the functional contribution of Nkx2.3, a putative CIC specific transcription factor identified in the OCMP, to OSCC aggressiveness and metastasis. In particular, we will aim to identify Nkx2.3 targets that may be therapeutically relevant. Thus, using complementary approaches extending from a mouse model, to genomic approaches and including active CIC targeted clinical trial specimens, we propose to delineate the molecular underpinnings and signatures that may have diagnostic and therapeutic relevance in patients with OSCC.

Public Health Relevance

The treatment of oral squamous cell carcinoma (OSCC) is complicated by recurrences and metastasis that likely arise from subsets of cancer cells within the tumor commonly referred to as cancer initiating cell (CIC) populations. Using data identified in mouse models of oral cancer, we have defined a molecular signature that we believe is CIC specific and shows robust predictive capacity in humans with OSCC. To extend this work, using genomic and other methods we propose to significantly advance our understanding of the molecular basis of human OSCC CIC aggressiveness towards improving diagnostic and therapeutic approaches for afflicted patients.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
1R01DE024403-01
Application #
8722269
Study Section
Special Emphasis Panel (ZDE1)
Program Officer
Venkatachalam, Sundaresan
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Washington University
Department
Otolaryngology
Type
Schools of Medicine
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63130